scholarly journals DUOC-01, a Cell Therapy Product Derived from Human Cord Blood, Accelerates Remyelination

2018 ◽  
Vol 7 ◽  
pp. S5-S5
Author(s):  
Arjun Saha
Keyword(s):  
Cell Therapy ◽  
Cord Blood ◽  
Human Cord Blood ◽  
Cell Therapy Product ◽  
A Cell

Gene products promoting remyelination are up-regulated in a cell therapy product manufactured from banked human cord blood

Cytotherapy ◽  
2017 ◽  
Vol 19 (6) ◽  
pp. 771-782 ◽  
Author(s):  
Paula Scotland ◽  
Susan Buntz ◽  
Pamela Noeldner ◽  
Arjun Saha ◽  
Tracy Gentry ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Cord Blood ◽  
Gene Products ◽  
Human Cord Blood ◽  
Cell Therapy Product ◽  
A Cell

scholarly journals Preclinical Evaluation and Optimization of a Cell Therapy Using Human Cord Blood-Derived Endothelial Colony-Forming Cells for Ischemic Retinopathies

2017 ◽  
Vol 7 (1) ◽  
pp. 59-67 ◽  
Author(s):  
Emma Reid ◽  
Jasenka Guduric-Fuchs ◽  
Christina L. O'Neill ◽  
Lynsey-Dawn Allen ◽  
Sarah E. J. Chambers ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Cord Blood ◽  
Human Cord Blood ◽  
Preclinical Evaluation ◽  
Endothelial Colony Forming Cells ◽  
A Cell

scholarly journals Human cord blood CD34+ progenitor cells acquire functional cardiac properties through a cell fusion process

2011 ◽  
Vol 300 (5) ◽  
pp. H1875-H1884 ◽  
Author(s):  
Daniele Avitabile ◽  
Alessia Crespi ◽  
Chiara Brioschi ◽  
Valeria Parente ◽  
Gabriele Toietta ◽  
...  
Keyword(s):  
Cord Blood ◽  
Cell Fusion ◽  
Fluorescent Protein ◽  
Lentiviral Vector ◽  
Fusion Process ◽  
Resting Potential ◽  
Human Cord Blood ◽  
Neonatal Cardiomyocytes ◽  
Cord Blood Cd34 ◽  
A Cell

The efficacy of cardiac repair by stem cell administration relies on a successful functional integration of injected cells into the host myocardium. Safety concerns have been raised about the possibility that stem cells may induce foci of arrhythmia in the ischemic myocardium. In a previous work ( 36 ), we showed that human cord blood CD34+ cells, when cocultured on neonatal mouse cardiomyocytes, exhibit excitation-contraction coupling features similar to those of cardiomyocytes, even though no human genes were upregulated. The aims of the present work are to investigate whether human CD34+ cells, isolated after 1 wk of coculture with neonatal ventricular myocytes, possess molecular and functional properties of cardiomyocytes and to discriminate, using a reporter gene system, whether cardiac differentiation derives from a (trans)differentiation or a cell fusion process. Umbilical cord blood CD34+ cells were isolated by a magnetic cell sorting method, transduced with a lentiviral vector carrying the enhanced green fluorescent protein (EGFP) gene, and seeded onto primary cultures of spontaneously beating rat neonatal cardiomyocytes. Cocultured EGFP+/CD34+-derived cells were analyzed for their electrophysiological features at different time points. After 1 wk in coculture, EGFP+ cells, in contact with cardiomyocytes, were spontaneously contracting and had a maximum diastolic potential (MDP) of −53.1 mV, while those that remained isolated from the surrounding myocytes did not contract and had a depolarized resting potential of −11.4 mV. Cells were then resuspended and cultured at low density to identify EGFP+ progenitor cell derivatives. Under these conditions, we observed single EGFP+ beating cells that had acquired an hyperpolarization-activated current typical of neonatal cardiomyocytes (EGFP+ cells, −2.24 ± 0.89 pA/pF; myocytes, −1.99 ± 0.63 pA/pF, at −125 mV). To discriminate between cell autonomous differentiation and fusion, EGFP+/CD34+ cells were cocultured with cardiac myocytes infected with a red fluorescence protein-lentiviral vector; under these conditions we found that 100% of EGFP+ cells were also red fluorescent protein positive, suggesting cell fusion as the mechanism by which cardiac functional features are acquired.

3075 – COMPARATIVE CLASSIFICATION OF HSCS SUBSETS IN HUMAN CORD BLOOD AND BONE MARROW SAMPLES:IMPLICATIONS FOR CELL THERAPY

2020 ◽  
Vol 88 ◽  
pp. S61
Author(s):  
Ameera Gaafar ◽  
Ayodele Alaiya ◽  
Rama Yousif ◽  
Zakia Shinwar Shinwar ◽  
Pulicat Subramanian ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cell Therapy ◽  
Cord Blood ◽  
Human Cord Blood

Cord blood derived cell therapy product, DUOC-01, accelerates remyelination in a murine model of cuprizone induced demyelination

Cytotherapy ◽  
2015 ◽  
Vol 17 (6) ◽  
pp. S55
Author(s):  
Arjun Saha ◽  
Susan Buntz ◽  
Sachit Patel ◽  
Marcia Bentz ◽  
David Snyder ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Cord Blood ◽  
Murine Model ◽  
Cell Therapy Product

scholarly journals Engineering of fully humanized and vascularized 3D bone marrow niches sustaining undifferentiated human cord blood hematopoietic stem and progenitor cells

2021 ◽  
Vol 12 ◽  
pp. 204173142110448
Author(s):  
Gordian Born ◽  
Marina Nikolova ◽  
Arnaud Scherberich ◽  
Barbara Treutlein ◽  
Andrés García-García ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cord Blood ◽  
Progenitor Cells ◽  
Stromal Vascular Fraction ◽  
Human Adipose Tissue ◽  
Human Cord Blood ◽  
Hematopoietic Stem ◽  
Stem And Progenitor Cells ◽  
A Cell ◽  
Modular Platform

Hematopoietic stem and progenitor cells (HSPCs) are frequently located around the bone marrow (BM) vasculature. These so-called perivascular niches regulate HSC function both in health and disease, but they have been poorly studied in humans due to the scarcity of models integrating complete human vascular structures. Herein, we propose the stromal vascular fraction (SVF) derived from human adipose tissue as a cell source to vascularize 3D osteoblastic BM niches engineered in perfusion bioreactors. We show that SVF cells form self-assembled capillary structures, composed by endothelial and perivascular cells, that add to the osteogenic matrix secreted by BM mesenchymal stromal cells in these engineered niches. In comparison to avascular osteoblastic niches, vascularized BM niches better maintain immunophenotypically-defined cord blood (CB) HSCs without affecting cell proliferation. In contrast, HSPCs cultured in vascularized BM niches showed increased CFU-granulocyte-erythrocyte-monocyte-megakaryocyte (CFU-GEMM) numbers. The vascularization also contributed to better preserve osteogenic gene expression in the niche, demonstrating that niche vascularization has an influence on both hematopoietic and stromal compartments. In summary, we have engineered a fully humanized and vascularized 3D BM tissue to model native human endosteal perivascular niches and revealed functional implications of this vascularization in sustaining undifferentiated CB HSPCs. This system provides a unique modular platform to explore hemato-vascular interactions in human healthy/pathological hematopoiesis.

scholarly journals A cord blood monocyte–derived cell therapy product accelerates brain remyelination

JCI Insight ◽  
2016 ◽  
Vol 1 (13) ◽  
Author(s):  
Arjun Saha ◽  
Susan Buntz ◽  
Paula Scotland ◽  
Li Xu ◽  
Pamela Noeldner ◽  
...  
Keyword(s):  
Cell Therapy ◽  
Cord Blood ◽  
Blood Monocyte ◽  
Cell Therapy Product

scholarly journals Human cord blood‐derived regulatory T ‐cell therapy modulates the central and peripheral immune response after traumatic brain injury

2020 ◽  
Vol 9 (8) ◽  
pp. 903-916 ◽  
Author(s):  
Henry W. Caplan ◽  
Karthik S. Prabhakara ◽  
Akshita Kumar ◽  
Naama E. Toledano‐Furman ◽  
Cecilia Martin ◽  
...  
Keyword(s):  
Traumatic Brain Injury ◽  
Immune Response ◽  
Brain Injury ◽  
T Cell ◽  
Cell Therapy ◽  
Cord Blood ◽  
Regulatory T Cell ◽  
Human Cord Blood ◽  
T Cell Therapy ◽  
Peripheral Immune Response

scholarly journals Regenerative treatment of spinal cord injury. Literature review. Part 4

2020 ◽  
Vol 22 (1) ◽  
pp. 83-92
Author(s):  
V. A. Smirnov ◽  
A. A. Grin
Keyword(s):  
Spinal Cord ◽  
Spinal Cord Injury ◽  
Cell Therapy ◽  
Cord Blood ◽  
Clinical Studies ◽  
Spinal Cord Injuries ◽  
Human Cord Blood ◽  
Limited Effectiveness ◽  
Cord Injury ◽  
Preclinical And Clinical Studies

Treating traumatic spinal cord injuries is one of the most complicated and relevant problems in the modern medicine. In the vast majority of cases spinal cord injury (SCI) leads to persistent disability, with medical, social and economic consequences ensuing for the patient, the family and the state. Modern SCI therapy has a very limited effectiveness and does not allow to sufficiently restore the lost functions of central nervous system. Regenerative methods and particularly cell therapy are very promising to effectively treat SCI. The review highlights SCI epidemiological and pathogenetic problems, existing therapy, as well as promising methods of regenerative therapy. We emphasize the results of preclinical and clinical studies in the field of cell therapy. The review is divided into 4 parts. In part 4, the use of human cord blood cells in SCI is discussed, in particular, the advantages of this type of therapy are considered, the composition of the cord blood cell mixture is described, and the results of preclinical and clinical studies are reported.

Sign in / Sign up

Export Citation Format

Share Document